BSE · 542678
Cian Healthcare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹31 Cr with net profit ₹-26 Cr — a -83.62% net margin, versus 1.37% the period before.
Shareholding
As of 2026-03-31
- Promoter95%
- Public5%
1,683 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.07× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — IBC. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #1 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Cian Healthcare Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashCian Healthcare Limited is listed with a market capitalization of Rs 49 Cr. The company reported a revenue of Rs 31.07 Cr and a net loss of Rs -25.98 Cr for the fiscal year ending March 2025. Its debt-to-equity ratio is 1.22.
Positives
- +The promoter holding increased from 70.89% in March 2021 to 95% in March 2026.
- +Promoter pledge is 0% as of March 31, 2026.
Negatives
- −Revenue decreased by 50.08% from Rs 62.14 Cr in March 2024 to Rs 31.07 Cr in March 2025.
- −The company reported a net loss of Rs -25.98 Cr in March 2025.
- −Earnings per share (EPS) declined to -10.39 in March 2025 from 0.34 in March 2024, representing a decrease of 3155.88%.
- −The debt-to-equity ratio is 1.22.
- −The company is currently under IBC surveillance.
Financial Performance
Cian Healthcare Limited's revenue decreased to Rs 31.07 Cr in March 2025 from Rs 62.14 Cr in March 2024. The company reported a net loss of Rs -25.98 Cr in March 2025, compared to a net profit of Rs 0.85 Cr in March 2024. Earnings per share (EPS) were -10.39 in March 2025, down from 0.34 in March 2024.
Balance Sheet
The company’s debt-to-equity ratio stands at 1.22. Further details regarding assets and liabilities are not provided in the supplied data.
Ownership & Pledges
Public shareholding is 5%. There is no promoter pledge reported as of March 31, 2026. The number of shareholders is 1683. Over time, promoter holding has increased from 70.89% in March 2021 to 95% in March 2026.
Regulatory & Surveillance
Cian Healthcare Limited is currently under the Insolvency and Bankruptcy Code (IBC) surveillance measure.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.